NUMANS Launches New DHA Algal Oil Products to Expand Portfolio

Stock News
06/10

NUMANS (HKG: 02530) has announced the launch of new DHA algal oil products as part of its portfolio expansion.

High-End Series — Children's DHA Algal Oil

The company has introduced a new product named "NUMANS® DHA Algal Oil (Containing Nervonic Acid)". This is an extension of the group's existing DHA algal oil line, formulated using DHA raw materials sourced from DSM, an internationally recognized nutritional ingredient supplier for the group's current products. The product targets children aged 6 to 16, extending the group's existing premium brand positioning into the school-age children segment.

Mid-Market Series — DHA Algal Oil with European-Imported Materials

The group has also launched a new series named "European Edition NUMANS® DHA Algal Oil", produced using raw materials imported from Europe. This series is positioned at a lower retail price point for the mid-market, aiming to address China's evolving consumption patterns and increasingly price-conscious consumer sentiment. The series covers pregnant women, infants, and school-age children.

All these new products are now available for purchase on the group's major online e-commerce platforms, covering general trade (import) and cross-border e-commerce models, as well as through the group's offline distribution channels.

The board believes the launch of these new products expands the group's product portfolio and customer base, extending its reach to a broader range of age groups and price points. The new product launches are still in their early stages, and their commercial performance will be influenced by factors including market acceptance, consumer demand, and competition. Therefore, there is no guarantee that the new products will achieve expected sales or make a significant contribution to the group's financial performance.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10